A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz(German Cancer Research Center), Carmen Scheibenbogen(University of Freiburg), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Antonia Busse(Franklin University), Anne Marie Asemissen(Franklin University), Lutz Uharek(Franklin University), Wolf-Karsten Hofmann(Franklin University), Anne Letsch(Franklin University), Eckhard Thiel(Franklin University), Sandra Bauer(Charité - Universitätsmedizin Berlin)
Cited by 300
Related Papers
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
|New England Journal of Medicine|2002|3.3k
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
|The Lancet|2008|642
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2019|621
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
|The Oncologist|2011|579